Reply to the letter to the editor: Two-year results of treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

被引：0
|
作者：
Masahiro Morimoto
Hidetaka Matsumoto
Kensuke Mimura
Hideo Akiyama
机构：
[1] Gunma University,Department of Ophthalmology
[2] School of Medicine,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2018年 / 256卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 226
页数：1
相关论文
共 50 条
  • [21] Two-Year Results of a Treat and Extend Regimen with Aflibercept in Caucasian Patients with Pachychoroid Neovasculopathy
    Hernandez, Javier Montero
    Sargues, Lidia Remoli
    Adsuara, Clara Monferrer
    Navarro, Veronica Castro
    Palop, Catalina Navarro
    Taulet, Enrique Cervera
    SEMINARS IN OPHTHALMOLOGY, 2023, 38 (04) : 352 - 357
  • [22] Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy
    Kurashige, Yumiko
    Otani, Atsushi
    Sasahara, Manabu
    Yodoi, Yuko
    Tamura, Hiroshi
    Tsuikawa, Akitaka
    Yoshimura, Nagahisa
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 146 (04) : 513 - 519
  • [23] Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
    Kikushima, Wataru
    Sakurada, Yoichi
    Sugiyama, Atsushi
    Yoneyama, Seigo
    Tanabe, Naohiko
    Matsubara, Mio
    Mabuchi, Fumihiko
    Iijima, Hiroyuki
    SCIENTIFIC REPORTS, 2017, 7
  • [24] Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
    Wataru Kikushima
    Yoichi Sakurada
    Atsushi Sugiyama
    Seigo Yoneyama
    Naohiko Tanabe
    Mio Matsubara
    Fumihiko Mabuchi
    Hiroyuki Iijima
    Scientific Reports, 7
  • [25] Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
    Okada, Annabelle A.
    Takahashi, Kanji
    Ohji, Masahito
    Moon, SungChul Charles
    Machewitz, Tobias
    Sasaki, Koji
    ADVANCES IN THERAPY, 2022, 39 (06) : 2984 - 2998
  • [26] Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
    Annabelle A. Okada
    Kanji Takahashi
    Masahito Ohji
    SungChul Charles Moon
    Tobias Machewitz
    Koji Sasaki
    Advances in Therapy, 2022, 39 : 2984 - 2998
  • [27] Two-year results of a treat and extend regimen with aflibercept in Caucasian patients with aneurysmal type 1 neovascularization
    Montero Hernandez, Javier
    Remoli Sargues, Lidia
    Monferrer Adsuara, Clara
    Castro Navarro, Veronica
    Navarro Palop, Catalina
    Cervera Taulet, Enrique
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : 377 - 384
  • [28] ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
    Hara, Chikako
    Sawa, Miki
    Sayanagi, Kaori
    Nishida, Kohji
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (01): : 37 - 45
  • [29] One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
    Yamamoto, Akiko
    Okada, Annabelle A.
    Kano, Mariko
    Koizumi, Hideki
    Saito, Masaaki
    Maruko, Ichiro
    Sekiryu, Tetsuju
    Iida, Tomohiro
    OPHTHALMOLOGY, 2015, 122 (09) : 1866 - 1872
  • [30] One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy
    Rouvas, Alexandros
    Gouliopoulos, Nikolaos
    Douvali, Maria
    Koutsocheras, Georgios
    Theodorou, Maria
    Bouratzis, Nikolaos
    Bougatsou, Panagiota
    Theodossiadis, Panagiotis
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (06) : 2868 - 2875
12345